The $358M Bet on a Cancer Target That Keeps Breaking Hearts

That single success cracked open a door that Terremoto is now trying to kick wide open.

Terremoto's Secret Weapon: Picking the Lock, Not Blowing Up the Door

Terremoto isn't building another pan-AKT inhibitor. Its approach is selective, targeting only AKT1 rather than all three isoforms. Think of it like this: if pan-AKT inhibitors are a shotgun blast in a crowded room, Terremoto's drugs are a sniper rifle aimed at one specific bad guy.

The company's chemistry platform is what makes this possible. Founded in 2022 by a trio of heavyweights (UCSF professors Matt Jacobson and Jack Taunton, plus serial biotech founder Peter Thompson), Terremoto uses lysine-targeted covalent chemistry to build its drugs. Most covalent drugs in oncology, including blockbusters like osimertinib and ibrutinib, latch onto a different amino acid called cysteine. By targeting lysine instead, Terremoto can access proteins and binding sites that previous drugs simply couldn't reach.

The lead candidate, TER-2013, is already in a Phase 1 trial for solid tumors carrying PIK3CA, AKT1, or PTEN mutations. Behind it sits TER-4480, an AKT1 inhibitor designed for hereditary hemorrhagic telangiectasia (HHT), a rare disease that causes abnormal blood vessel formation. TER-4480 is still in pre-clinical safety studies but is expected to enter Phase 1 later this year.

Follow the Money

The $108 million Series C wasn't raised in a vacuum. This brings Terremoto's total funding to roughly $358 million across three rounds: a $75 million Series A in 2022, a $175 million Series B in 2023, and now this. That's an enormous war chest for a company with only one drug in the clinic.

The investor roster reads like a who's who of biotech venture capital. New backers include RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Returning investors OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management all doubled down. When existing investors keep writing checks, it generally signals conviction rather than desperation.

The company's leadership adds credibility too. CEO Charles Baum joined in 2024 after founding and running Mirati Therapeutics, which Bristol Myers Squibb acquired that same year. Before Mirati, he led programs at Pfizer responsible for drugs like Ibrance, Xalkori, and Inlyta. The man has a track record of turning targeted oncology programs into approved products.

The Market Is Watching

Terremoto isn't the only company eyeing this space. According to some estimates, the global AKT inhibitor market is projected to grow at roughly 15% annually, potentially reaching $6 to $8 billion by 2033, though other analyses project more modest growth. AstraZeneca's Truqap dominates today, but companies like Vaderis Inc. (developing VAD0044, a subtype-selective AKT inhibitor out-licensed from Almac Discovery) and Taiho Pharmaceutical are developing their own candidates.

Broader oncology investment trends are also working in Terremoto's favor. Oncology remains the top therapeutic area for venture capital, pharma partnerships, and pipeline programs. And while overall biotech VC funding dipped to a six-year low in 2025, the back half of the year saw a rebound, with about 60% of all VC dollars landing in the second half. Analysts are cautiously optimistic that 2026 will be stronger.

The Real Question

Can selectivity solve what brute force couldn't? That's the billion-dollar question hanging over Terremoto. AKT1-only inhibition should, in theory, deliver better efficacy with fewer of the metabolic side effects that plagued earlier drugs. Capivasertib already proved that picking the right patients matters; Terremoto is betting that picking the right isoform matters just as much.

Phase 1 data for TER-2013 will be the first real test. It won't tell us if the drug cures cancer, but it will reveal whether the selectivity translates into a cleaner safety profile. If hyperglycemia and other toxicities stay low while the drug shows signs of tumor activity, the earthquake metaphor might actually land.

If not, the AKT graveyard gets another headstone. And $358 million in venture money becomes a very expensive geology lesson.

The Biotech Field That Didn't Exist a Decade Ago Just Got Its Biggest Bet Yet

Storm Therapeutics just raised $56 million and dosed the first patient in a Phase 2 sarcoma trial, all for a drug targeting an enzyme most people have never heard of. It's the biggest clinical milestone yet for epitranscriptomics, a therapeutic field that literally didn't exist a decade ago.